Study: Psilocybin Shows Potential Promise in Treating Cocaine Addiction
Researchers found psilocybin with psychotherapy led to more cocaine-free days and 30% complete abstinence at 180 days, the study said.
- A new study published in JAMA Network Open reveals a single dose of psilocybin combined with psychotherapy significantly increased cocaine abstinence in patients with cocaine use disorder.
- Targeting historically underrepresented groups, the trial enrolled 40 participants—mostly Black men earning less than $20,000 annually—to address the lack of FDA-approved pharmacological treatments for cocaine use disorder.
- Results showed 30% of psilocybin recipients achieved complete abstinence through 180 days, compared to 0% in the placebo group, with no serious adverse events reported.
- Lead investigator Peter Hendricks, professor in the Department of Psychiatry and Behavioral Neurobiology, stated results are promising but require larger, multisite trials to confirm broader applicability.
- These clinical findings emerge amid an expanding federal push to accelerate psychedelic research, including President Donald Trump's April 18 executive order facilitating access to psychedelic drugs for eligible patients.
19 Articles
19 Articles
It is psilocybin, a promising fungal derivative against the disorder.Researchers from the USA, Britain and Sweden successfully tested it in volunteers. 30% still did not use cocaine 180 days after the dose of the drug received.
Psychedelics’ trip to mainstream medicine comes with risk
The White House directive to put psychedelics on a regulatory fast track is at once welcome and worrisome. The attention to psychedelics is overdue, and there’s a real opportunity to build a stronger scientific base for a promising field. The post Psychedelics’ trip to mainstream medicine comes with risk appeared first on Hawaii Tribune-Herald.
Lawmakers Press FDA to Expedite Psychedelic Therapies for Mental Health
More than two dozen lawmakers are calling on the U.S. Food and Drug Administration (FDA) to expedite its review of mental health therapies like psychedelics as part of multiple pieces of legislation already drafted.
Coverage Details
Bias Distribution
- 60% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
